Head-to-Head trial aims to find best drug for tough blood cancer
NCT ID NCT07498205
Summary
This study directly compares two already-approved drugs, momelotinib and ruxolitinib, for people newly diagnosed with myelofibrosis who also have low blood cell counts. The main goal is to see which drug is better at shrinking an enlarged spleen and reducing the need for blood transfusions. Researchers will also track side effects and how well each drug controls other disease symptoms over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.